Reading ELUT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ELUT free→Reading ELUT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ELUT free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, but the capital stance is capital unfriendly. Risk is low, while the sector backdrop presents a headwind, and compared with sector peers, ELUT is below typical. Peer multiples imply a price about 6% below where it trades (it looks expensive on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.95. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.97 ELUT trades at 1× p/e, below its 23× p/e peer median. Our $0.89 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 9% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.12x of net income into operating cash flow.
Not enough signal yet.
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.15 → $-0.15 (+0.0% / 30d). 0 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Not enough price history for this read.
How much price usually moves either way.
Not enough price history for this read.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $952.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth picks up, it could signal a recovery for Elutia and its peers.
Confirms:A reported revenue growth rate for the health care sector above 10% year over year.
Disproves:Revenue growth is still under 10% year over year. This shows the sector is still weak.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ELUT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ELUT Elutia Inc | Below typical Show detailsSector percentile: 10 of 100 | full | low |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 54 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 88 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Elutia aims to support a gross margin target of more than 80% at scale.
Newly stated in 2026-Q1. The company has set a target to achieve a gross margin of over 80% at scale. However, the current gross profit for 2026-Q1 is $1.8 million on revenue of $3.1 million, indicating limited progress towards this target.
“supporting a gross margin target of more than 80% at scale”
Elutia is focused on improving its operating income, which has been negative.
Stated in 3 of last 3 quarters. Operating income improved from negative $9.9 million in 2025-Q2 to negative $6.3 million in 2026-Q1, showing progress but still negative. The trajectory indicates some improvement, but further efforts are needed to reach positive operating income.
“Operating income was reported as negative $6.3 million.”
Elutia is working to increase its revenue, which has shown fluctuations.
Stated in 3 of last 3 quarters. Revenue decreased from $6.3 million in 2025-Q2 to $3.1 million in 2026-Q1, indicating a declining trend. Despite management's focus on growth, the financials show limited progress in increasing revenue.
“Revenue for 2026-Q1 was $3.1 million.”
“Revenue was $3.3 million.”
Why it matters: The earnings date will show how well the company is doing. It will also give clues about future plans.
Confirms one read:An announcement of the next earnings date within the next month.
Confirms the other:There is no news on the next earnings date. This creates uncertainty about how the company is doing.
The filing describes amendments to the company's incentive award plan, not a management change.
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 3, 2026, the Board of Directors (the "Board") of Elutia Inc. (the "Company") adopted the Elutia Inc. 2026 Inducement Award Plan (the "Inducement Plan"). The purpose of the Inducement Plan is to induce individuals to enter into enter into employment with the Company and its subsidiaries, and to enhance the ability of the Company and its sub…
Results of Operations and Financial Condition. On January 12, 2026, Elutia Inc. (the “Company” or “Elutia”) issued a press release announcing its preliminary results for the fourth quarter ended December 31, 2025. The preliminary results are subject to normal year-end accounting closing and audit procedures. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this
“Operating income was negative $5.2 million.”
“Operating income was negative $9.9 million.”
“Revenue was $6.3 million.”